Europe’s Newest Biotech – Valneva – Formed As Intercell And Vivalis Marry
This article was originally published in The Pink Sheet Daily
Executive Summary
One of the few remaining independent biotech vaccine developers in Europe, Austria's Intercell, is to join forces with France's Vivalis in a proposed merger valued at $174 million to create a pipeline spanning from antibodies to vaccines.